RECRUITING

Aromatherapy Essential Oils to Manage Anxiety and Nausea in Cancer Patients Receiving Infusion in the Ambulatory Setting

Conditions

Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This clinical trial tests how well aromatherapy essential oils work to manage anxiety and nausea in cancer patients receiving infusions in the ambulatory setting. Current drugs that are given for nausea may cause constipation and fatigue. Therefore, there is interest in exploring complementary therapies, like aromatherapy, that do not carry the same side effects. Using aromatherapy essential oils such as ginger, peppermint, and lavender, may help reduce nausea and anxiety. Some studies have shown significant reductions in nausea and anxiety among cancer patients using these oils, while other studies have had mixed results. Ginger and peppermint oils, in particular, have been associated with helping reduce nausea during chemotherapy, while lavender has shown potential benefits for anxiety. Jojoba oil will be used as a placebo for this research study. Jojoba oil is extracted from the seeds of a jojoba plant, which is a green shrub that is found in the southwestern United States). Jojoba oil is an oil which has no color or smell. Aromatherapy essential oils used through a personal inhalation device during chemotherapy may better manage anxiety and nausea in cancer patients receiving infusions in the ambulatory setting.

Official Title

Assessing the Feasibility of Aromatherapy Essential Oil Associated Changes on Nausea in Patients Receiving Infusion in the Ambulatory Setting

Quick Facts

Study Start:2025-07-08

Study Completion:2027-01-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT07126301

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Patients must have the ability to understand and sign a written informed consent document, and be willing to follow protocol requirements * Ability to read and understand English for patient reported outcomes * Age \>= 18 years * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 * Willingness to comply with all study interventions of essential oil aromatherapy * Have been on a moderate- to high-risk emetogenic chemotherapy regimen as defined by the National Comprehensive Cancer Network (NCCN) for at least 1 cycle of therapy * At least 2 remaining infusion appointments on a moderate- to high-risk emetogenic chemotherapy regimen as defined by the NCCN * Have nausea defined as \> 3/10 with last chemotherapy infusion based on screening symptom questionnaire * The study is open to all participants regardless of gender, race, or ethnicity	* Self-reported aversion or sensitivity to lavender oil, peppermint oil, ginger oil, jojoba oil * Uncontrolled respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) * Mental incapacitation (ex. stroke, brain metastasis etc.) that would cause inability to follow directions, in the opinion of the investigators * Ongoing uncontrolled active psychiatric condition that would interfere in the conduct of the study (e.g., mood disorders, anxiety, psychosis disorders, or substance use) * Self-reported abnormal smelling abilities (for ex: ongoing sinus infections, long covid, etc.) * Aromatherapy use in the last 30 days

Inclusion Criteria

Exclusion Criteria

* Patients must have the ability to understand and sign a written informed consent document, and be willing to follow protocol requirements
* Ability to read and understand English for patient reported outcomes
* Age \>= 18 years
* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
* Willingness to comply with all study interventions of essential oil aromatherapy
* Have been on a moderate- to high-risk emetogenic chemotherapy regimen as defined by the National Comprehensive Cancer Network (NCCN) for at least 1 cycle of therapy
* At least 2 remaining infusion appointments on a moderate- to high-risk emetogenic chemotherapy regimen as defined by the NCCN
* Have nausea defined as \> 3/10 with last chemotherapy infusion based on screening symptom questionnaire
* The study is open to all participants regardless of gender, race, or ethnicity

* Self-reported aversion or sensitivity to lavender oil, peppermint oil, ginger oil, jojoba oil
* Uncontrolled respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD)
* Mental incapacitation (ex. stroke, brain metastasis etc.) that would cause inability to follow directions, in the opinion of the investigators
* Ongoing uncontrolled active psychiatric condition that would interfere in the conduct of the study (e.g., mood disorders, anxiety, psychosis disorders, or substance use)
* Self-reported abnormal smelling abilities (for ex: ongoing sinus infections, long covid, etc.)
* Aromatherapy use in the last 30 days

Contacts and Locations

Principal Investigator

Richard T Lee

PRINCIPAL_INVESTIGATOR

City of Hope Medical Center

Study Locations (Sites)

City of Hope Medical Center

Duarte, California, 91010

United States

City of Hope at Irvine Lennar

Irvine, California, 92618

United States

Collaborators and Investigators

Sponsor: City of Hope Medical Center

Richard T Lee, PRINCIPAL_INVESTIGATOR, City of Hope Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-07-08

Study Completion Date2027-01-01

Study Record Updates

Study Start Date2025-07-08

Study Completion Date2027-01-01

Terms related to this study

Additional Relevant MeSH Terms

Hematopoietic and Lymphatic System Neoplasm
Malignant Solid Neoplasm